Cell Medica

Cell Medica is committed to transforming patients’ lives through developing cellular immunotherapies to treat cancer. In collaboration with our strategic partners, Cell Medica is developing products using three proprietary technologies: activated T cells, chimeric antigen receptors (CARs) and  engineered T cell receptors (TCRs). Our lead product CMD-003 is being tested in two Phase II trials for treating Epstein Barr virus-associated cancers. We are working with Baylor College of Medicine and the University of North Carolina to develop next generation CAR-modified NKT cells,  including off-the- shelf products. We are collaborating with University College London to develop the Dominant TCR technology platform.